Resmed (RMD) Depreciation & Amortization (CF) (2009 - 2026)

Resmed (RMD) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $59.0 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 35.05% year-over-year to $59.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220.2 million (up 23.34% YoY) and the FY2025 annual result came in at $198.5 million, up 12.21% from the prior year.
• Depreciation & Amortization (CF) rose to $59.0 million in Q1 2026, from $49.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $63.6 million in Q2 2025 to a low of $36.3 million in Q3 2022.
• A 5-year average of $45.7 million and a median of $44.7 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) dropped 7.41% — and 2025, when it surged 45.68%.
• Tracing RMD's Depreciation & Amortization (CF) over 5 years: stood at $37.8 million in 2022, then climbed by 18.58% to $44.8 million in 2023, then grew by 3.7% to $46.4 million in 2024, then rose by 7.42% to $49.9 million in 2025, then advanced by 18.23% to $59.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $59.0 million (Q1 2026), $49.9 million (Q4 2025), and $47.7 million (Q3 2025), per Business Quant data.